Cellosaurus cell line ADK-VR2 (CVCL

Cellosaurus ADK-VR2 (CVCL_E6J5)

[Text version]

Cell line name

ADK-VR2

Accession

CVCL_E6J5

Resource Identification Initiative

To cite this cell line use: ADK-VR2 (RRID:CVCL_E6J5)

Comments

Population: Southeast Asian; Filipino.
Doubling time: 34.88 hours (Direct_author_submission).
Omics: Genomics; Whole exome sequencing.
Omics: Transcriptomics; RNAseq.
Donor information: Established from a treatment-naive non-smoker patient (PubMed=36519016).
Miscellaneous: Doubling time and ethnic origin of patient from personal communication of Angelicola, Stefania.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:10661; SDC4; Name(s)=SDC4-ROS1; Note=SDC4 exon 2 fused to ROS exon 32 (PubMed=36519016).

Disease

Lung adenocarcinoma (NCIt: C3512)

Species of origin

Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy

Children:

CVCL_E6J6 (ADK-VR2 AG143)

Sex of cell

Male

Age at sampling

46Y

Category

Cancer cell line

Publications

PubMed=36519016; DOI=10.21037/tlcr-22-163; PMCID=PMC9742620
Francesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, Elena Nironi, Maria Sofia Semprini, Laura Scalambra, Annalisa Altimari, Elisa Gruppioni, Michelangelo Fiorentino, Francesca Giunchi, Manuela Ferracin ...Show all 18 authors... , Annalisa Astolfi, Valentina Indio, Andrea Ardizzoni, Francesco Gelsomino, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini; Show fewer authors
ADK-VR2, a cell line derived from a treatment-naive patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Transl. Lung Cancer Res. 11:2216-2229(2022)

Entry history

Entry creation

10-Apr-2025

Last entry update

10-Apr-2025

Version number